Download PDF
Thromb Haemost 2005; 94(06): 1341-1343
DOI: 10.1055/s-0037-1615590
Letter to the Editor
Schattauer GmbH

Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis

Adriana M. W. van Marion
1   Department of Haematology, 2Department of Pathology, University
2   Medical Centre Utrecht, 3Department of Haematology, Erasmus
,
Johannes J. A. Auwerda
3   Medical Centre Rotterdam
,
Monique C. Minnema
4   Department of Internal Medicine, Academic Medical Centre Amsterdam, The Netherlands
,
Rolinda van Oosterom
1   Department of Haematology, 2Department of Pathology, University
,
Jelle Adelmeijer
1   Department of Haematology, 2Department of Pathology, University
,
Philip G. de Groot
1   Department of Haematology, 2Department of Pathology, University
,
Frank W. G. Leebeek
3   Medical Centre Rotterdam
,
Pieter Sonneveld
3   Medical Centre Rotterdam
,
Henk M. Lokhorst
1   Department of Haematology, 2Department of Pathology, University
,
Ton Lisman
1   Department of Haematology, 2Department of Pathology, University
› Author Affiliations
Further Information

Publication History

Received 26 May 2005

Accepted after resubmission 17 September 2005

Publication Date:
11 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951-2.
    CrossrefPubMedSearch in Google Scholar
  • 2 Zangari M, Siegel E, Barlogie B. et al Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168-71.
    CrossrefPubMedSearch in Google Scholar
  • 3 Minnema MC, Fijnheer R, de Groot PG. et al Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1: 445-9.
    CrossrefPubMedSearch in Google Scholar
  • 4 Zangari M, Saghafifar F, Mehta P. et al The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003; 29: 275-82.
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Deitcher SR, Choueiri T, Srkalovic G. et al Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. Br J Haematol 2003; 123: 959.
    CrossrefPubMedSearch in Google Scholar
  • 6 Carr Jr. ME, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 1996; 128: 83-8.
    CrossrefPubMedSearch in Google Scholar
  • 7 Yagci M, Sucak GT, Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol 2003; 74: 231-7.
    CrossrefPubMedSearch in Google Scholar
  • 8 Lisman T, de Groot PG, Meijers JC. et al Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-5.
    CrossrefPubMedSearch in Google Scholar
  • 9 Minnema MC, Breitkreutz I, Auwerda JJ. et al Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18: 2044-6.
    CrossrefPubMedSearch in Google Scholar
  • 10 Francis CW. Plasminogen activator inhibitor-1 levels and polymorphisms. Arch Pathol Lab Med 2002; 126: 1401-4.
    PubMedSearch in Google Scholar
  • 11 Ridker PM, Vaughan DE, Stampfer MJ. et al Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissuetype plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1822-7.
    CrossrefPubMedSearch in Google Scholar
  • 12 Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151: 1721-31.
    CrossrefPubMedSearch in Google Scholar
  • 13 Lisman T, Leebeek FW, Mosnier LO. et al Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-9.
    CrossrefPubMedSearch in Google Scholar
  • 14 Lisman T, Adelmeijer J, Nieuwenhuis HK. et al Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting factor Xa, but not by those inhibiting thrombin or tissue factor. Blood Coag Fibrinol 2003; 14: 557-62.
    CrossrefPubMedSearch in Google Scholar